About the Study: Are novel autoantibodies associated with idiopathic myelopathy? In this case-control study, autoantibodies targeting the transcobalamin receptor (CD320) responsible for cellular transport of vitamin B12 were identified in a portion of individuals with idiopathic myelopathy, especially those whose disease mimicked subacute combined degeneration. Screening for anti-CD320 followed by metabolic confirmation of a central nervous system-restricted vitamin B12 deficiency may be considered in the diagnostic evaluation of myelopathy.
Corresponding Authors: John V. Pluvinage, MD, PhD, Department of Neurology, University of California, San Francisco, 1651 Fourth St, Ste 212, San Francisco, CA 94158 (john.pluvinage@ucsf.edu); Michael R. Wilson, MD, MAS, Department of Neurology, University of California, San Francisco, 675 Nelson Rising Ln, NS212, Campus Box 3206, San Francisco, CA 94143 (michael.wilson@ucsf.edu).
10.1001/jamaneurol.2026.2778
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Journal
JAMA Neurology